P01280674A05
The_DD corresponding_VVGJ figures_NNS in_II the_DD control_NN patients_NNS were_VBD 8_MC and_CC 3_MC days_NNS ,_, respectively_RR (_( P_NN <_SYM .0001_MC )_) ._.
P01281454A02
Interleukin-1_NN (_( IL-1_NN )_) ;_: 4-40_MC ng_NN /_SYM ml_NN and_CC E._NN coli_NN lipopolysaccharide_NN (_( LPS_NN )_) ;_: 0.1-1.00_MC ng_NN /_SYM ml_NN ,_, were_VBD the_DD most_RRT effective_JJ stimuli_NNS and_CC induced_VVD dose-dependent_JJ secretion_NN of_II both_CC GM-CSF_NN and_CC G-CSF_NN ._.
P01281539A03
These_DD survival_NN rates_NNS were_VBD improved_VVN by_II BMT_NN ._.
P01282065A01
Murine_JJ BCL-1_NN B-cell_NN leukemia_NN provides_VVZ a_DD model_NN of_II disseminated_VVNJ human_NN B-lineage_NN acute_JJ lymphoblastic_JJ leukemia_NN (_( ALL_NN )_) and_CC non-Hodgkins_NN lymphoma_NN (_( NHL_NN )_) ._.
P01282573A01
A_DD 9-year-old_JJ boy_NN with_II chronic_JJ granulomatous_JJ disease_NN was_VBD hospitalized_VVN on_II May_NN ,_, 1991_MC ,_, because_II+ of_II continued_VVNJ fever_NN and_CC pain_NN in_II the_DD right_JJ elbow_NN ._.
P01372661A11
This_DD remedy_NN will_VM become_VVB useful_JJ for_II completion_NN of_II the_DD schedule_NN and_CC dose_NN intensification_NN of_II chemotherapy_NN in_II the_DD future_NN ._.
P01375042A02
Dose_NN modification_NN factor_NN was_VBD 1.20_MC when_CS 4.5_MC micrograms_NNS /_SYM mouse_NN of_II rhG-CSF_NN was_VBD given_VVN daily_RR for_II 14_MC days_NNS after_II whole_JJ body_NN irradiation_NN ._.
P01375161A04
Splenic_JJ erythropoiesis_NN effectively_RR compensated_VVD for_II the_DD loss_NN of_II marrow_NN erythropoiesis_NN as_CS indicated_VVN by_II the_DD maintenance_NN of_II a_DD normal_JJ hematocrit_NN ._.
P01379475A06
However_RR ,_, the_DD second_JJ phase_NN of_II aggregation_NN induced_VVN by_II epinephrine_NN was_VBD significantly_RR inhibited_VVN by_II 1.0_MC ng_NN /_SYM ml_NN G-CSF_NN ._.
P01380074A01
We_PN report_VVB a_DD patient_NN with_II congenital_JJ neutropenia_NN or_CC Kostmann_NN 's_GE Syndrome_NN who_PNR suffered_VVD many_DD complications_NNS after_II presenting_VVGN with_II Clostridium_NN septicum_NN enterocolitis_NN ,_, including_VVG absence_NN of_II wound_NN healing_VVGN ._.
P01380571A10
(_( ABSTRACT_NN TRUNCATED_VVN AT_II 250_MC WORDS_NNS )_)
P01381543A01
We_PN tested_VVD the_DD in_JJ+ vitro_JJ effect_NN of_II a_DD novel_JJ granulocyte_NN colony-stimulating_VVGJ factor_NN (_( G-CSF_NN )_) derivative_NN (_( KW-2228_NN )_) on_II the_DD growth_NN of_II G-CSF-dependent_JJ hemopoietic_JJ progenitor_NN cells_NNS :_: granulocyte_NN precursor_NN cells_NNS (_( CFU-G_NN )_) ,_, leukemic_JJ blast_NN progenitors_NNS freshly_RR obtained_VVN from_II 9_MC patients_NNS with_II acute_JJ myeloblastic_JJ leukemia_NN (_( AML_NN )_) and_CC cells_NNS of_II a_DD G-CSF-dependent_JJ human_NN AML_NN cell_NN line_NN (_( OCI_NN /_SYM AML_NN 1a_NN )_) ._.
P01383355A08
No_DD adverse_JJ effects_NNS of_II G-CSF_NN were_VBD observed_VVN ._.
P01384899A11
To_II date_NN ,_, five_MC of_II the_DD patients_NNS have_VHB been_VBN transplanted_VVN with_II autologous_JJ marrow_NN harvested_VVN after_II rhG-CSF_NN treatment_NN ._.
P01696146A05
In_JJ+ vivo_JJ rhIL-3_NN had_VHD no_DD effect_NN on_II the_DD recurrent_JJ neutropenia_NN but_CC was_VBD associated_VVN with_II eosinophilia_NN ,_, rhGM-CSF_NN caused_VVNJ neutrophilia_NN and_CC eosinophilia_NN but_CC cycling_VVGN of_II hematopoiesis_NN persisted_VVD ._.
P01698477A03
GM-CSF_NN stimulated_VVD increased_VVNJ CFU-GM_NN growth_NN in_II the_DD 16_MC patients_NNS with_II abnormal_JJ marrow_NN cytogenetics_NNS in_II comparison_NN with_II the_DD 20_MC patients_NNS who_PNR had_VHD normal_JJ cytogenetics_NNS (_( 52_MC and_CC 30_MC colonies_NNS per_II 10_MC (_( 5_MC )_) NAB_NN ,_, respectively_RR ,_, P_NN less_RR than_CSN .05_MC )_) ,_, whereas_CS no_DB such_DD difference_NN could_VM be_VBB demonstrated_VVN with_II G-CSF_NN (_( 11_MC and_CC 16_MC colonies_NNS per_II 10_MC (_( 5_MC )_) NAB_NN ,_, respectively_RR )_) ._.
P01698896A05
Moreover_RR G-CSF_NN enhanced_VVD a_DD protective_JJ effect_NN to_II pulmonary_JJ and_CC systemic_JJ pseudomonas_NN infections_NNS ._.
P01703795A07
However_RR ,_, three_MC sequential_JJ daily_JJ additions_NNS of_II 150_MC ng_NN /_SYM mL_NN G-CSF_NN did_VDD stimulate_VVB primitive_JJ progenitors_NNS to_TO enter_VVI S-phase_NN and_CC a_DD single_JJ addition_NN of_II 5_MC or_CC 12.5_MC ng_NN /_SYM mL_NN of_II G-CSF_NN together_RR with_II 10_MC ng_NN /_SYM mL_NN GM-CSF_NN was_VBD able_JJ to_TO elicit_VVI the_DD same_JJ effect_NN ._.
P01705433A06
A_DD chemical_JJ cross-linking_VVGJ study_NN revealed_VVD that_CST the_DD G-CSF_NN receptor_NN has_VHZ an_DD approximate_JJ molecular_JJ weight_NN of_II 140,000_MC ._.
P01705636A02
Granulocyte-macrophage_NN colony-stimulating_VVGJ factor_NN (_( GM-CSF_NN )_) stimulated_VVD the_DD proliferation_NN of_II HL-60_NN cells_NNS in_II a_DD dose-dependent_JJ manner_NN at_II concentrations_NNS of_II 0.01-100_MC ng_NN /_SYM ml_NN ;_: however_RR ,_, the_DD proliferation_NN due_II+ to_II GM-CSF_NN was_VBD suppressed_VVN by_II 100_MC nM_NN RA_NN ._.
P01707693A07
GM-CSF_NN and_CC G-CSF_NN (_( 1_MC ng_NN /_SYM mL_NN to_II 1_MC microgram_NN /_SYM mL_NN )_) had_VHD no_DD effect_NN on_II the_DD expression_NN of_II either_CC tissue_NN plasminogen_NN activator_NN (_( tPA_NN )_) or_CC plasminogen_NN activator_NN inhibitor-1_NN (_( PAI-1_NN )_) by_II endothelial_JJ cells_NNS ._.
P01709109A02
We_PN determined_VVD WBC_NN counts_NNS ,_, differentials_NNS ,_, the_DD number_NN of_II total_JJ nucleated_VVNJ cells_NNS ,_, the_DD myeloid_NN mitotic_JJ pool_NN cells_NNS (_( promyelocytes_NNS and_CC myelocytes_NNS )_) ,_, the_DD storage_NN pool_NN cells_NNS (_( metamyelocytes_NNS ,_, bands_NNS ,_, and_CC polymorphonuclear_JJ cells_NNS [_( PMNs_NNS ]_) )_) and_CC the_DD granulocyte-macrophage_NN (_( granulocyte-macrophage_NN colony-forming_VVGJ units_NNS ,_, CFU-GM_NN )_) and_CC macrophage_NN (_( macrophage_NN colony-forming_VVGJ units_NNS ,_, CFU-M_NN )_) progenitor_NN cells_NNS of_II the_DD bone_NN marrow_NN ,_, spleen_NN ,_, and_CC the_DD liver_NN before_II the_DD first_JJ dose_NN of_II rhG-CSF_NN administration_NN and_CC 12_MC h_NN after_II the_DD second_JJ ,_, fourth_JJ ,_, and_CC sixth_JJ dose_NN ._.
P01709372A09
The_DD stimulated_VVNJ monocyte_NN production_NN in_II the_DD case_NN of_II G-CSF_NN required_VVD an_DD additional_JJ five_MC cell_NN cycles_NNS ,_, a_DD level_NN that_PNR might_VM have_VHB repercussions_NNS on_II the_DD progenitor_NN compartments_NNS ._.
P01710148A01
We_PN tested_VVD the_DD ability_NN of_II recombinant_JJ human_NN stem_NN cell_NN factor_NN (_( SCF_NN )_) to_TO stimulate_VVI isolated_VVNJ marrow_NN precursor_NN cells_NNS to_TO form_VVI colonies_NNS in_II semisolid_JJ media_NN and_CC to_TO generate_VVI colony-forming_VVGJ cells_NNS (_( CFC_NN )_) in_II liquid_JJ culture_NN ._.
P01710151A05
Not_RR only_RR was_VBD rG-CSF_NN radioprotective_JJ at_II much_RR smaller_JJR doses_NNS than_CSN rGM-CSF_NN ,_, the_DD survival_NN rate_NN after_II lethal_JJ TBI_NN was_VBD also_RR significantly_RR higher_JJR in_II mice_NNS receiving_VVG optimally_RR radioprotective_JJ doses_NNS of_II rG-CSF_NN as_CS compared_VVN with_II mice_NNS receiving_VVG optimally_RR radioprotective_JJ doses_NNS of_II rGM-CSF_NN ._.
P01712246A08
These_DD data_NNS indicated_VVD that_CST PEG-rhG-CSF_NN administration_NN exerted_VVD a_DD sustained_VVNJ biological_JJ effect_NN on_II peripheral_JJ blood_NN neutrophils_NNS ._.
P01714327A10
The_DD high_JJ expression_NN of_II Fc_NN gamma_NN RI_NN during_II rhG-CSF_NN therapy_NN correlated_VVD with_II enhanced_VVNJ cytotoxicity_NN ._.
P01714401A10
By_II day_NN 19_MC ,_, neutrophil_NN levels_NNS had_VHD dropped_VVN significantly_RR (_( p_NN less_RR than_CSN 0.01_MC )_) from_II the_DD maximum_NN neutrophil_NN levels_NNS ,_, with_II one_MC cat_NN attaining_VVGN a_DD normal_JJ blood_NN neutrophil_NN count_NN by_II day_NN 21_MC of_II rhG-CSF_NN treatment_NN ._.
P01716591A01
Functional_JJ activity_NN of_II peripheral_JJ blood_NN granulocytes_NNS was_VBD assessed_VVN in_II seven_MC patients_NNS and_CC in_II their_PNG normal_JJ donors_NNS following_VVG allogeneic_JJ bone_NN marrow_NN transplantation_NN (_( BMT_NN )_) ._.
P02471275A06
The_DD initial_JJ dose_NN of_II GM-CSF_NN in_II some_DD patients_NNS produced_VVD a_DD reaction_NN that_PNR was_VBD characterized_VVN by_II hypoxia_NN ._.
P07506671A05
In_II sharp_JJ contrast_NN to_II patients_NNS receiving_VVG GM-CSF_NN ,_, however_RR ,_, progenitor_NN cells_NNS from_II patients_NNS off_II G-CSF_NN treatment_NN for_II 2_MC to_II 4_MC days_NNS were_VBD still_RR rapidly_RR proliferating_VVG ._.
P07509223A04
Interestingly_RR ,_, 10_MC out_II+ of_II the_DD 27_MC patients_NNS showed_VVD a_DD dramatic_JJ improvement_NN in_II severe_JJ anemia_NN after_II two_MC to_II ten_MC months_NNS of_II therapy_NN ._.
P07509672A03
There_EX were_VBD no_DD granulocytes_NNS in_II the_DD peripheral_JJ smear_NN and_CC a_DD bone_NN marrow_NN biopsy_NN demonstrated_VVD an_DD absence_NN of_II the_DD entire_JJ myeloid_NN cell_NN line_NN as_CC+ well_CC+ as_CC the_DD presence_NN of_II many_DD granulomas_NNS ._.
P07510423A08
White_JJ blood_NN cells_NNS (_( WBC_NN )_) were_VBD counted_VVN at_II day_NN 2_MC after_II treatment_NN ._.
P07512833A10
The_DD stimulation_NN index_NN of_II marrow_NN mononuclear_JJ cells_NNS cultured_VVN with_II rhG-CSF_NN increased_VVD with_II disease_NN progression_NN ._.
P07520770A02
Such_DD limitations_NNS seem_VVB to_TO predispose_VVI infected_VVNJ newborns_NNS to_II neutropenia_NN from_II an_DD exhaustion_NN of_II the_DD neutrophil_NN reserve_NN ._.
P07520770A15
The_DD rhG-CSF_NN was_VBD well_RR tolerated_VVN at_II all_DD gestational_JJ ages_NNS treated_VVN ._.
P07521347A13
On_II the_DD other_JJ hand_NN ,_, recovery_NN time_NN was_VBD significantly_RR shorter_JJR in_II group_NN C_NN (_( 6.8_MC +/-_SYM 1.2_MC days_NNS mean_NN +/-_SYM SE_NN )_) compared_VVN with_II groups_NNS A_NN and_CC B_NN (_( P_NN <_SYM 0.05_MC )_) ._.
P07521693A06
CTLs_NNS primed_VVN against_II the_DD BM_NN donor_NN suppressed_VVD the_DD formation_NN of_II colonies_NNS consisting_VVG of_II granulocytes_NNS and_CC macrophages_NNS (_( colony-forming_VVGJ unit_NN GM_NN )_) ._.
P07522393A06
When_CS compared_VVN to_II GM-CSF_NN ,_, G-CSF_NN significantly_RR reduced_VVD the_DD duration_NN of_II granulocytopenia_NN (_( P_NN <_SYM .001_MC )_) ._.
P07525173A04
The_DD results_NNS indicated_VVD that_CST rhG-CSF_NN (_( GRAN_NN )_) could_VM elevate_VVB nadirs_NNS of_II WBC_NN and_CC significantly_RR shortened_VVD leukopenic_JJ period_NN with_II WBC_NN below_II 4.0_MC x_SYM 10_MC (_( 9_MC )_) /_SYM L_NN and_CC expedited_VVD the_DD recovery_NN of_II WBC_NN ._.
P07525676A07
We_PN examined_VVD G-CSF_NN and_CC GM-CSF_NN mRNA_NN expressions_NNS in_II peripheral_JJ mononuclear_JJ cells_NNS stimulated_VVN with_II LPS_NN ,_, PMA_NN ,_, and_CC Con_NN A_NN by_II Northern_NN hybridization_NN ._.
P07526017A01
In_II order_NN to_TO evaluate_VVI the_DD mobilization_NN effect_NN of_II recombinant_JJ human_NN granulocyte_NN colony-stimulating_VVGJ factor_NN (_( rhG-CSF_NN )_) on_II peripheral_JJ blood_NN stem_NN cells_NNS (_( PBSCs_NNS )_) ,_, rhG-CSF_NN was_VBD given_VVN to_II patients_NNS with_II urogenital_JJ malignancy_NN before_II chemotherapy_NN ._.
P07528570A06
Parallel_JJ to_II this_DD increase_NN in_II CD34+_NN cells_NNS ,_, clonogenic_JJ assays_NNS showed_VVD a_DD corresponding_VVGJ increase_NN in_II CFU-GM_NN and_CC BFU-E_NN ._.
P07529843A07
However_RR ,_, he_PN relapsed_VVD in_II May_NN ,_, 1991_MC with_II 46XY_NN ,_, 16q-_NN ,_, i_NN (_( 17q_NN )_) chromosome_NN ._.
P07530405A06
A_DD dose_NN of_II 400_MC micrograms_NNS /_SYM m2_NN G-CSF_NN was_VBD sufficient_JJ to_TO cause_VVI an_DD increase_NN in_II neutrophil_NN count_NN and_CC 100_MC IU_NN /_SYM kg_NN rhEPO_NN appeared_VVD to_TO be_VBI sufficient_JJ to_TO cause_VVI an_DD increase_NN in_II erythrocyte_NN count_NN ._.
P07531290A08
The_DD number_NN of_II C._NN albicans_NN colony-forming_VVGJ units_NNS (_( CFU-C._NN albicans_NN )_) in_II the_DD kidney_NN of_II infected_VVNJ mice_NNS was_VBD lower_JJR in_II the_DD rhG-CSF-treated_VVNJ group_NN than_CSN in_II the_DD non-treated_VVNJ control_NN mice_NNS ._.
P07533820A02
The_DD induction_NN of_II Fc_NN gamma_NN RI_NN by_II rhG-CSF_NN has_VHZ previously_RR been_VBN reported_VVN to_TO result_VVI from_II effects_NNS on_II immature_JJ granulocyte_NN progenitors_NNS ._.
P07535143A07
The_DD presence_NN of_II receptors_NNS for_II SCF_NN in_II ALL_NN was_VBD confirmed_VVN by_II polymerase_NN chain_NN reaction_NN for_II c-kit_NN mRNA_NN in_II 19_MC /_SYM 21_MC cases_NNS tested_VVN ._.
P07539959A06
Similar_JJ synergistic_JJ increases_NNS of_II other_JJ hematopoietic_JJ progenitors_NNS ,_, such_II+ as_II colony-forming_VVGJ units_NNS in_II spleen_NN and_CC megakaryocyte_NN colony-forming_VVGJ units_NNS in_II blood_NN ,_, were_VBD also_RR observed_VVN in_II mice_NNS co-administered_VVN rhIL-6_NN and_CC rhG-CSF_NN ._.
P07541325A04
Each_DD patient_NN received_VVD two_MC cycles_NNS treatment_NN ._.
P07541523A01
Recombinant_JJ human_NN granulocyte_NN (_( rhG_NN )_) colony-stimulating_VVGJ factor_NN (_( CSF_NN )_) and_CC recombinant_JJ human_NN granulocyte-macrophage_NN (_( rhGM_NN )_) CSF_NN have_VHB been_VBN used_VVN to_TO enhance_VVI neonatal_JJ neutrophil_NN host_NN defense_NN ._.
P07545214A09
The_DD other_JJ responder_NN had_VHD normal_JJ ALT_NN until_II the_DD first_JJ month_NN of_II follow-up_NN ._.
P07556528A02
The_DD longer_JJR the_DD duration_NN of_II cytokine_NN treatment_NN ,_, the_DD higher_JJR the_DD stimulatory_JJ effect_NN on_II stem_NN cell_NN mobilization_NN ._.
P07584671A01
The_DD influence_NN of_II CSF_NN therapy_NN on_II the_DD superoxide_NN (_( O2-_NN )_) releasing_VVGJ capacity_NN in_II response_NN to_II N-formyl-methionyl-leucyl-phenylalanine_NN (_( FMLP_NN )_) of_II neutrophils_NNS from_II 32_MC patients_NNS with_II testicular_JJ cancer_NN receiving_VVG high-dose_NN chemotherapy_NN followed_VVN by_II autologous_JJ bone_NN marrow_NN transplantation_NN (_( ABMT_NN )_) was_VBD assessed_VVN :_: 8_MC patients_NNS were_VBD treated_VVN as_II control_NN group_NN without_II CSF_NN therapy_NN ,_, 12_MC patients_NNS received_VVD GM-CSF_NN ,_, and_CC 12_MC patients_NNS received_VVD G-CSF_NN ._.
P07678512A01
Interleukin-8_NN (_( IL-8_NN )_) is_VBZ a_DD major_JJ neutrophil_NN chemoattractant_NN and_CC functional_JJ stimulant_NN that_PNR is_VBZ induced_VVN by_II IL-1_NN ,_, tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF_NN alpha_NN )_) ,_, and_CC lipopolysaccharide_NN (_( LPS_NN )_) ._.
P07679062A06
The_DD priming_VVGJ effect_NN of_II rhGM-CSF_NN was_VBD consistently_RR greater_JJR than_CSN that_PND of_II rhG-CSF_NN in_II each_DD patient_NN ._.
P07680373A07
Dose-intensity_NN was_VBD well_RR maintained_VVN through_II three_MC cycles_NNS of_II therapy_NN ,_, after_II which_PNR leukopenia_NN and_CC thrombocytopenia_NN became_VVD dose-limiting_VVGN ._.
P07680849A05
(_( Variant_NN type_NN of_II E._NN coli_NN is_VBZ now_RR in_II trial._NN )_) Difference_NN of_II these_DD two_MC is_VBZ whether_CST carbohydrate_NN chain_VVB primarily_RR seen_VVN in_II molecule_NN of_II natural_JJ form_NN is_VBZ contained_VVN or_CC not_RR ._.
P07681699A01
Two_MC hematopoietic_JJ colony-stimulating_VVGJ factors_NNS ,_, granulocyte_NN colony-stimulating_VVGJ factor_NN (_( G-CSF_NN )_) and_CC granulocyte-macrophage_NN CSF_NN (_( GM-CSF_NN )_) ,_, have_VHB been_VBN shown_VVN to_TO accelerate_VVI leukocyte_NN and_CC neutrophil_NN recovery_NN after_II high-dose_NN chemotherapy_NN and_CC autologous_JJ bone_NN marrow_NN (_( BM_NN )_) support_NN ._.
P07681704A07
GM-CSF_NN priming_VVGN markedly_RR increased_VVD PMN_NN superoxide_NN release_NN (_( sevenfold_NN )_) ,_, but_CC PMN_NN superoxide_NN release_NN was_VBD not_RR further_RR enhanced_VVN by_II the_DD presence_NN of_II MNLs_NNS ._.
P07683484A01
We_PN studied_VVD the_DD long-term_NN in_JJ+ vivo_JJ effect_NN of_II recombinant_JJ human_NN granulocyte_NN colony_NN stimulating_VVGJ factor_NN (_( rhG-CSF_NN )_) on_II in_JJ+ vitro_JJ growth_NN of_II granulocyte_NN /_SYM macrophage_NN colony_NN forming_VVGJ cells_NNS (_( GM-CFC_NN )_) in_II bone_NN marrow_NN and_CC peripheral_JJ blood_NN obtained_VVN from_II two_MC patients_NNS with_II autoimmune_JJ neutropenia_NN ,_, who_PNR received_VVD rhG-CSF_NN ._.
P07685198A01
The_DD bromodeoxyuridine_NN (_( BrdU_NN )_) -Hoechst_NN flow_NN cytometric_JJ technique_NN was_VBD applied_VVN to_TO study_VVI the_DD immediate_JJ cell_NN kinetic_JJ response_NN of_II highly_RR purified_VVNJ human_NN (_( h_NN )_) bone_NN marrow_NN progenitor_NN cells_NNS (_( CD_NN (_( 34+_MC )_) -sorted_VVNJ fraction_NN )_) to_II h_NN granulocyte_NN colony-stimulating_VVGJ factor_NN (_( G-CSF_NN )_) and/or_CC h_NN granulocyte-macrophage_NN colony-stimulating_VVGJ factor_NN (_( GM-CSF_NN )_) ._.
P07687221A02
In_II addition_NN ,_, the_DD possibility_NN of_II synergism_NN between_II erythropoietin_NN (_( Epo_NN )_) and_CC G-CSF_NN in_II blood_NN stem_NN cell_NN mobilization_NN was_VBD studied_VVN ._.
P07689123A03
In_II the_DD 1st_JJ course_NN ,_, when_CS no_DD rhG-CSF_NN was_VBD administered_VVN ,_, the_DD neutrophil_NN function_NN declined_VVD significantly_RR (_( p_NN <_SYM 0.01_MC )_) as_CS the_DD peripheral_JJ neutrophil_NN count_NN (_( PNC_NN )_) decreased_VVD ,_, reached_VVD the_DD minimum_NN almost_RR at_II the_DD same_JJ day_NN as_CS PNC_NN reached_VVD the_DD nadir_NN ,_, and_CC returned_VVD to_II the_DD normal_JJ level_NN at_II the_DD beginning_VVGN of_II the_DD next_JJ course_NN ._.
P07691244A08
An_DD average_NN of_II 3.04_MC x_SYM 10_MC (_( 10_MC )_) CD3+_NN cells_NNS were_VBD collected_VVN per_II pheresis_NN ._.
P07691413A01
Granulocyte_NN colony-stimulating_VVGJ factor_NN (_( G-CSF_NN )_) is_VBZ a_DD cytokine_NN that_PNR regulates_VVZ the_DD proliferation_NN and_CC differentiation_NN of_II neutrophils_NNS ._.
P07693032A07
Despite_II an_DD abnormal_JJ responsiveness_NN of_II mature_JJ myeloid_NN progenitors_NNS to_II G-CSF_NN in_II this_DD SCN_NN patient_NN ,_, myeloid_NN progenitors_NNS responsive_JJ to_II the_DD combination_NN of_II stem_NN cell_NN factor_NN (_( SCF_NN )_) and_CC G-CSF_NN showed_VVD normal_JJ dose-response_NN ._.
P08542941A13
Our_PNG results_NNS demonstrated_VVD that_CST pretreatment_NN with_II G-CSF_NN modified_VVD the_DD response_NN of_II BM_NN cells_NNS to_II subsequent_JJ stimulation_NN with_II additional_JJ CSFs_NNS ._.
P08605651A04
The_DD leukocyte_NN count_NN was_VBD 1,100_MC /_SYM mm3_NN with_II 23_MC %_SYM granulocytes_NNS ,_, 76_MC %_SYM lymphocytes_NNS and_CC 1_MC %_SYM monocytes_NNS ._.
P08610118A09
These_DD findings_NNS support_VVB a_DD model_NN whereby_CST binding_VVGN of_II E21R_NN to_II the_DD alpha_NN chain_NN leads_VVZ to_II apoptosis_NN ,_, while_CS beta_NN (_( c_NN )_) plays_VVZ an_DD important_JJ role_NN in_II cell_NN survival_NN ._.
P08632675A05
Receptor_NN binding_VVGJ analysis_NN revealed_VVD that_CST L-8801_NN cells_NNS expressed_VVD a_DD G-CSF_NN receptor_NN (_( Kd=125_NN pM_NN ,_, 479_MC binding_VVGJ sites_NNS /_SYM cell_NN )_) and_CC L-8057_NN cells_NNS had_VHD no_DD G-CSF_NN receptors_NNS ._.
P08636780A06
No_DD clinically_RR significant_JJ difference_NN was_VBD observed_VVN between_II the_DD two_MC groups_NNS concerning_VVG days_NNS of_II absolute_JJ neutropenia_NN or_CC neutropenic_JJ fever_NN ._.
P08647235A07
On_II day_NN 3_MC ,_, mean_NN CD34+_NN cell_NN counts_NNS of_II the_DD subjects_NNS who_PNR received_VVD sequential_JJ treatment_NN were_VBD markedly_RR higher_JJR than_CSN observed_VVN in_II the_DD other_JJ groups_NNS (_( p_NN <_SYM 0.05_MC )_) and_CC were_VBD estimated_VVN to_TO have_VHI been_VBN sufficient_JJ for_II collection_NN of_II adequate_JJ grafts_NNS by_II single_JJ 10-L_NN leukapheresis_NN procedures_NNS in_II 60_MC %_SYM of_II subjects_NNS ._.
P08749950A02
Reduction_NN of_II leukopenia_NN during_II chemotherapy_NN has_VHZ been_VBN demonstrated_VVN by_II the_DD combined_VVNJ administration_NN of_II granulocyte_NN colony-stimulating_VVGJ factor_NN (_( G-CSF_NN )_) in_II various_JJ malignancies_NNS ._.
P08757506A02
This_DD study_NN investigated_VVD whether_CST G-CSF_NN is_VBZ able_JJ to_TO directly_RR influence_VVI the_DD transendothelial_JJ migration_NN of_II neutrophils_NNS ,_, and_CC how_CST such_DD effects_NNS might_VM be_VBB related_VVN to_II other_JJ effects_NNS on_II neutrophil_NN adhesive_JJ properties_NNS ._.
P08843219A04
Free_JJ radical_NN formation_NN in_II defective_JJ PMNL_NN was_VBD enhanced_VVN by_II rhG-CSF_NN to_II a_DD level_NN similar_JJ to_II that_PND found_VVN in_II normal_JJ PMNL_NN primed_VVN by_II rhG-CSF_NN ._.
P08918500A10
Pooled_VVN together_RR ,_, patients_NNS who_PNR received_VVD IL-3_NN showed_VVD a_DD median_JJ time_NN to_TO achieve_VVI a_DD granulocyte_NN count_NN greater_JJR than_CSN 0.1_MC and_CC greater_JJR than_CSN 0.5_MC x_SYM 10_MC (_( 9_MC )_) /_SYM L_NN of_II 8_MC and_CC 11_MC days_NNS ,_, respectively_RR ._.
P08973623A08
Pretreatment_NN with_II rhG-CSF_NN resulted_VVD in_II increased_VVNJ tissue_NN myeloperoxidase_NN levels_NNS ,_, despite_II a_DD histologically_RR similar_JJ mucosal_JJ polymorphonuclear_JJ cell_NN infiltrate_NN between_II treated_VVNJ and_CC control_NN colitis_NN groups_NNS ._.
P09028941A13
Moreover_RR ,_, G-CSF_NN administration_NN prevented_VVD apoptosis_NN in_II a_DD small_JJ but_CC significant_JJ proportion_NN of_II mobilized_VVNJ CD34+_NN cells_NNS ._.
P09218602A03
Only_RR rhGM-CSF_NN affected_VVD mast_JJ cell_NN development_NN ._.
P09326222A01
Thrombopoietin_NN (_( TPO_NN )_) was_VBD evaluated_VVN for_II efficacy_NN in_II a_DD placebo-controlled_VVNJ study_NN in_II rhesus_NN monkeys_NNS with_II concurrent_JJ administration_NN of_II either_CC granulocyte_NN /_SYM macrophage_NN colony-stimulating_VVGJ factor_NN (_( GM-CSF_NN )_) or_CC granulocyte_NN CSF_NN ,_, (_( G-CSF_NN )_) ._.
P09326222A14
administration_NN of_II TPO_NN is_VBZ sufficient_JJ to_TO prevent_VVI severe_JJ thrombocytopenia_NN following_VVG myelosuppression_NN ,_, (_( 2_MC )_) TPO_NN /_SYM G-CSF_NN and_CC TPO_NN /_SYM GM-CSF_NN treatment_NN result_VVB in_II distinct_JJ response_NN patterns_NNS ,_, with_II TPO_NN /_SYM GM-CSF_NN being_VVGN superior_JJ to_II TPO_NN /_SYM G-CSF_NN in_II stimulating_VVGJ thrombocyte_NN and_CC erythrocyte_NN recovery_NN while_CS being_VBG equivalent_JJ in_II stimulating_VVGN neutrophil_NN recovery_NN ;_: and_CC (_( 3_MC )_) TPO_NN significantly_RR improves_VVZ the_DD performance_NN of_II CSFs_NNS in_II alleviating_VVGN severe_JJ neutropenia_NN ._.
P09339749A04
No_DD changes_NNS of_II lymphocyte_NN response_NN to_II pokeweed_NN mitogen_NN were_VBD observed_VVN ._.
P09345066A08
While_CS GM-CSF_NN and_CC G-CSF_NN alone_JJ had_VHD little_DD effect_NN on_II BM_NN CFU_NN over_II time_NN ,_, FL_NN alone_JJ increased_VVD CFU-GM_NN and_CC CFU-GEMM_NN threefold_NN and_CC fivefold_NN ,_, respectively_RR ._.
P09365526A09
Circulating_VVGJ anti-G-CSF_NN antibodies_NNS did_VDD not_RR seem_VVB to_TO affect_VVI hematological_JJ recovery_NN ._.
P09377071A10
We_PN conclude_VVB that_CST PIXY321_NN and_CC G-CSF_NN act_VVB synergistically_RR on_II the_DD in_JJ+ vitro_JJ proliferation_NN and_CC neutrophil_NN differentiation_NN of_II BM_NN and_CC PB_NN CD34+_NN cells_NNS and_CC that_CST frequent_JJ supplements_NNS of_II G-CSF_NN facilitate_VVB neutrophil_NN differentiation_NN ._.
P09528829A01
The_DD effects_NNS of_II altering_VVGN the_DD timing_VVGN of_II recombinant_JJ human_NN granulocyte_NN colony-stimulating_VVGJ factor_NN (_( rhG-CSF_NN )_) administration_NN on_II neutropenia_NN induced_VVN by_II cyclophosphamide_NN (_( CPA_NN )_) were_VBD studied_VVN experimentally_RR in_II a_DD mouse_NN model_NN ._.
P09544974A05
RhG-CSF_NN was_VBD infused_VVN continuously_RR at_II a_DD dose_NN of_II 5_MC microg_NN /_SYM kg_NN /_SYM day_NN ,_, starting_VVG 24_MC hr_NN before_II the_DD initial_JJ dose_NN of_II total_JJ body_NN irradiation_NN (_( TBI_NN )_) until_II the_DD end_NN of_II AraC_NN therapy_NN ._.
P09592847A06
The_DD contribution_NN of_II rhG-CSF_NN to_II clinical_JJ recovery_NN warrants_VVZ further_JJ investigation_NN ._.
P09818688A06
The_DD patients_NNS received_VVD dexamethasone_NN 24_MC mg_NN days_NNS 1-7_MC ,_, melphalan_NN 30_MC mg_NN /_SYM m2_NN day_NN 3_MC ,_, BCNU_NN 60_MC mg_NN /_SYM m2_NN day_NN 3_MC ,_, etoposide_NN 75_MC mg_NN /_SYM m2_NN days_NNS 4-7_MC ,_, Ara-C_NN 100_MC mg_NN /_SYM m2_NN twice_RR daily_JJ days_NNS 4-7_MC (_( Dexa-BEAM_NN )_) ._.
P10473803A04
The_DD main_JJ findings_NNS were_VBD that_CST (_( a_NN )_) granulocyte_NN and_CC lymphocyte_NN recovery_NN rates_NNS were_VBD faster_JJR in_II the_DD patients_NNS receiving_VVG G-CSF_NN ;_: (_( b_NN )_) looking_VVG at_II the_DD lymphocyte_NN compartment_NN ,_, this_DD difference_NN was_VBD restricted_VVN to_II the_DD CD3_NN (_( +_SYM )_) /_SYM CD8_NN (_( +_SYM )_) and_CC CD56_NN (_( +_SYM )_) lymphocyte_NN subsets_NNS ;_: (_( c_NN )_) the_DD reconstitution_NN rate_NN of_II CD19_NN (_( +_SYM )_) lymphocytes_NNS was_VBD slow_JJ in_II both_DD groups_NNS ;_: (_( d_NN )_) at_II the_DD end_NN of_II follow-up_NN HLA-DR_NN expression_NN by_II CD3_NN (_( +_SYM )_) lymphocytes_NNS was_VBD higher_JJR in_II the_DD GM-CSF_NN group_NN ;_: (_( e_NN )_) the_DD lymphocyte_NN proliferative_JJ capacity_NN was_VBD restored_VVN at_II a_DD faster_JJR rate_NN in_II the_DD GM-CSF_NN group_NN ,_, whereas_CS cytotoxic_JJ activities_NNS recovered_VVD better_RRR in_II the_DD G-CSF_NN group_NN ;_: (_( f_NN )_) the_DD early_JJ repopulating_VVGJ phase_NN was_VBD characterized_VVN by_II higher_JJR interleukin-6_NN serum_NN levels_NNS in_II the_DD GM-CSF_NN group_NN ._.
P10550313A03
G-CSF_NN ,_, GM-CSF_NN ,_, and/or_CC their_PNG receptors_NNS were_VBD expressed_VVN in_II all_DD tumors_NNS and_CC derived_VVNJ cell_NN cultures_NNS ,_, but_CC coexpression_NN of_II both_CC factors_NNS and_CC receptors_NNS was_VBD almost_RR exclusively_RR found_VVN in_II grade_NN IV_MC glioblastomas_NNS and_CC thus_RR correlated_VVD with_II advanced_VVNJ tumor_NN stage_NN ._.
P10708106A01
BACKGROUND_NN :_: Leukopenia_NN due_II+ to_II immunosuppressive_JJ drugs_NNS represents_VVZ a_DD well-known_VVNJ complication_NN in_II graft_NN recipients_NNS ,_, which_PNR might_VM put_VVB patients_NNS at_II an_DD increased_VVNJ risk_NN for_II infections_NNS ._.
P10708106A14
CONCLUSION_NN :_: rhG-CSF_NN was_VBD safe_JJ and_CC effective_JJ in_II leukopenic_JJ kidney_NN graft_NN recipients_NNS ._.
P10784622A10
Three_MC of_II the_DD seven_MC patients_NNS in_II whom_PNR mobilization_NN was_VBD poor_JJ after_II G1_NN had_VHD >_SYM or_CC =2x10_NN (_( 6_MC )_) CD34_NN (_( +_SYM )_) cells_NNS /_SYM kg_NN with_II two_MC leukaphereses_NNS after_II C2_NN ._.
P11146160A08
In_II contrast_NN ,_, inclusion_NN of_II both_CC G-CSF_NN and_CC hydrocortisone_NN in_II the_DD cytokine_NN "_`` cocktail_NN "_'' markedly_RR increased_VVD the_DD neutrophil_NN numbers_NNS ._.
P11283939A06
METHODS_NNS :_: In_II this_DD study_NN ,_, 10_MC ovarian_JJ carcinoma_NN biopsies_NNS were_VBD characterized_VVN for_II the_DD presence_NN of_II G-CSF_NN and_CC G-CSF_NN receptor_NN by_II reverse_JJ transcription-polymerase_NN chain_NN reaction_NN (_( RT-PCR_NN )_) and_CC immunohistochemical_JJ analysis_NN ._.
P11440552A03
The_DD purpose_NN of_II this_DD study_NN was_VBD to_TO test_VVI that_DD hypothesis_NN ._.
P11740262A11
However_RR ,_, RI_NN ,_, LIS_NN ,_, and_CC TM_NN did_VDD not_RR change_VVB ,_, suggesting_VVG that_CST no_DD patient_NN developed_VVD lung_NN injury_NN ._.